IRIS
CRETELLA, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.017
AS - Asia 1.334
EU - Europa 1.203
SA - Sud America 244
AF - Africa 71
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.872
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.985
SG - Singapore 531
CN - Cina 454
IT - Italia 287
IE - Irlanda 218
BR - Brasile 202
SE - Svezia 200
FI - Finlandia 118
DE - Germania 112
HK - Hong Kong 103
VN - Vietnam 83
ZA - Sudafrica 47
IN - India 46
NL - Olanda 43
GB - Regno Unito 39
AT - Austria 36
TR - Turchia 34
BE - Belgio 32
FR - Francia 26
RU - Federazione Russa 20
AR - Argentina 19
CA - Canada 18
ID - Indonesia 16
PL - Polonia 15
UA - Ucraina 15
CZ - Repubblica Ceca 12
JP - Giappone 11
CI - Costa d'Avorio 10
ES - Italia 10
MX - Messico 10
BD - Bangladesh 8
EC - Ecuador 8
IQ - Iraq 8
LT - Lituania 6
PK - Pakistan 6
CO - Colombia 5
TN - Tunisia 5
UZ - Uzbekistan 5
IR - Iran 4
KG - Kirghizistan 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EG - Egitto 3
KR - Corea 3
LU - Lussemburgo 3
AL - Albania 2
CH - Svizzera 2
CL - Cile 2
DZ - Algeria 2
HU - Ungheria 2
JO - Giordania 2
LB - Libano 2
QA - Qatar 2
SA - Arabia Saudita 2
AO - Angola 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PE - Perù 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.872
Salva come PNG Salva come JPEG
Città #
Singapore 289
Chandler 246
Ann Arbor 240
Dublin 218
Dallas 217
Ashburn 198
Parma 126
Santa Clara 124
Hong Kong 103
Beijing 90
Dearborn 85
Boardman 64
Munich 54
Shanghai 52
New York 51
Johannesburg 44
Los Angeles 43
Nanjing 40
Princeton 35
Izmir 32
Vienna 31
Bremen 27
Ho Chi Minh City 26
Helsinki 23
Brussels 21
Hanoi 21
Wilmington 21
Shenyang 20
Nanchang 19
Jinan 17
Buffalo 16
Hebei 16
Kunming 16
Redmond 16
São Paulo 16
Woodbridge 15
Columbus 14
Des Moines 14
Hefei 14
Jakarta 14
San Mateo 14
Pune 12
Wayne 12
Tianjin 11
Abidjan 10
Denver 10
Jiaxing 10
Norwalk 10
Toronto 10
Turku 10
Warsaw 10
Chennai 9
Guangzhou 9
Phoenix 9
Rio de Janeiro 9
Tokyo 9
Dong Ket 8
Frankfurt am Main 8
Manchester 8
Modena 8
Rio Saliceto 8
Seattle 8
The Dalles 8
Binche 7
Brno 7
Fremont 7
Houston 7
Jacksonville 7
London 7
New Delhi 7
Stockholm 7
Brescia 6
Brooklyn 6
Changsha 6
Council Bluffs 6
Fuzhou 6
Moscow 6
Poplar 6
Rome 6
Belo Horizonte 5
Boston 5
Brasília 5
Chicago 5
Genoa 5
Leawood 5
Nuremberg 5
Redwood City 5
Baghdad 4
Bishkek 4
Bologna 4
Campinas 4
Haiphong 4
Mons 4
Recife 4
Tashkent 4
Ardabil 3
Augusta 3
Baku 3
Bắc Ninh 3
Cagliari 3
Totale 3.139
Salva come PNG Salva come JPEG
Nome #
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 207
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 185
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 181
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 179
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 170
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 165
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 164
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 156
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 153
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 149
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 147
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 141
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 140
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 138
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 136
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 133
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 132
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 132
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 129
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 122
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 118
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 115
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 113
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 112
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 110
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 103
CDK4/6 inhibitors in HER2-positive breast cancer 103
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 102
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 92
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 87
Targeting FGFR1 pathway in squamous cell lung cancer 83
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 70
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 62
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 42
Totale 4.978
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021203 0 0 0 0 0 16 19 31 36 22 43 36
2021/2022232 28 12 21 14 4 3 30 10 10 12 11 77
2022/2023877 80 107 61 69 82 102 4 57 261 3 40 11
2023/2024337 21 30 2 15 31 78 35 28 13 23 22 39
2024/20251.000 19 39 51 69 113 110 86 49 138 70 85 171
2025/20261.365 222 192 269 254 324 104 0 0 0 0 0 0
Totale 4.978